CROI 2017 Abstract e-Book

Abstract eBook

Keyword Index

· Immunology 232, 949 · Protection 210 Multicohort study 237LB

Nup358/RanBP2 17 Nutrition status 648

1044, 1047, 115, 29LB, 489, 767, 809 Maturation 158, 265LB, 507 Maturation inhibitor 507

Obesity 230, 356, 642, 698, 699 Observational cohort study 461 Obstructive lung disease 657 Occupational exposure 656 Older population 991 One-step PrEP 961 Ongoing replication 120 Online 901 Opiate substitution therapy 524, 555, 870 Opioid use 869, 871, 930 Opportunistic infection 82, 213, 348, 725, 731, 732, 737, 741, 750 Opt-out testing 957 Oral fluid 213 Oraquick 893 Osteoclast 680 Osteoporosis 678 Outbreak 185, 582, 878 Outcomes 464, 911 Oxidative stress 634, 647 P2X 256 P2X7 ATP receptors 256 PAI-1 692 Parent- offspring regression 191 Partner services 89, 189, 763, 958, 1032 Passive immunoprophylaxis 415 Pathogenesis 218, 647 Patient costs 994 Pattern 976 PBPK 423 PCR 791, 801 PD-1 331, 337, 800 Pediatrics 272, 707, 799, 804, 806, 809, 810, 29LB, 808, 812, 816, 829, 285, 800 Peer 111 Peer effect 36 Peginterferon alpha 579 Penicilliosis 83, 748 People living with HIV/AIDS 708, 861, 996, 997, 1007, 1019 People who inject drugs 185, 554, 559, 842, 870, 873, 1028 Peptide pools 310 Pericardial fat 634 Perinatal HIV exposure 25 Perinatal HIV infection 649, 775, 805, 814, 820, 825 Peripheral blood mononuclear cells 395 Persistence 1055LB, 289, 297, 303, 304, 370, 73 PET 628 Pharmacist 961 Pharmacology 39, 366, 384, 39, 40, 407, 408, 411, 413, 414, 415, 417, 418, 419, 420, 421LB, 427, 428, 429, 432, 753, 754, 755, 757, 758, 806, 807, 809, 810, 811, 938, 978 Pharmacy 961 Pharmacy refill 1001 Phenotypic resistance 505 pHSC 716LB Phylodynamic analysis 189 Phylodynamics 186 Phylogenetics 196, 197, 299LB, 365, 561, 848, 185, 318, 186, 193, 520 Optimized background therapy 460 Option B+ 686, 764, 766, 771, 782, 783 Oral 433

MCP-1 824 MCTC 760 Measurement 769 Measures of HIV-1 persistence 279 Medicaid 1012 Medical Male Circumcision, Tetanus, Kenya 985 Medical monitoring project 907, 922, 1012 Medication-Assisted Therapy 870 MELD 536 Memory CD4 T Cells 291

Multidrug resistance 449LB Multilevel modeling 1013 Multimerization Inhibitor 157 Multimorbidity 662 Multipurpose prevention technology 936 Mutation 246, 485 Mutation resistance 483 MxB 160LB Mycobacterium tuberculosis 715LB Myeloid cells 161 Myeloid derived suppressor cells 203 Myocardial infarction 127, 130, 625 Nadir CD4 626 Naive patients 41, 290, 357 Naltrexone 868LB Nanomedicine 39, 422LB NAT screening 867 Natural history 23 Natural reservoir 122 Navigation 111 Nef 175 Neisseria gonorrhoeae 948 Neonatal prophylaxis regimen 793

Men who have sex with men and women (MSMW) 852 Men who have sex with men (MSM) 89, 1024, 1028, 1033, 1034, 134, 186, 206, 2074, 248, 519, 520, 521, 524, 576, 596, 843, 846, 854, 855, 856, 862, 863, 867, 871, 873, 883, 886, 887, 891, 897, 898, 901, 902, 918, 91LB, 942, 966, 967, 971, 973, 977, 997 Menopause 940 Mental health 838 Mental health disorders 454, 556, 664, 746, 927 Mesoamerica 182 Metabolomics 636LB Metagenomics 215 Metformin 255 Methamphetamine 134, 871, 872, 873, 967 Methotrexate 414 Mexico 480 Mice qVOA 306 Microbial translocation 212, 215, 260LB, 526, 801 Microbicide 86LB, 936 Microbiome 87, 207, 208, 212, 213, 214, 216, 239 Microbiota 207, 636LB, 676, 802, 85, 86LB Micronutrients 648 Misdiagnosis 1031 Missed visit 1000 Mitochondria 229, 392, 691, 780 Mitochondrial toxicity 643 MIV-150 501 MK-8591 435, 440 Mobile technology 892 Mobility 210 Modeling 116, 129, 135, 596, 900, 1024, 1026, 1032, 1037, 1038 Molecular epidemiology 182, 183, 188, 191 Monocyte 125, 385, 395, 612, 829 Monocyte activation 341, 387, 617 Monocyte cholesterol efflux 613 Monocyte immune activation 381 Monocyte inflammation 205 Monotherapy 42, 437, 450LB, 451LB Morbidity 774 Mortality 37, 235, 471, 529, 581, 626, 630, 644, 645, 650, 665, 717, 742, 745, 774, 928, 931, 995 Mother-to-child transmission 753, 765, 767, 787, 788, 792 MicroRNA 537 Microscopy 308 Migrants 1015 Migration 860, 1018 Military 358, 932 Molecular mechanisms 680 Monitoring 848, 980, 1039 Monoclonal antibody 438, 449LB, 450LB

Neonates 757 Neopterin 340 Nephrotoxicity 686 Network models 1024 NeuroAIDS 371, 397

Neurocognitive 342, 353, 371, 380, 382, 388, 389, 826, 205, 343, 353, 354, 356, 360, 377, 381, 396, 665, 72, 339, 340, 343, 356, 390, 394, 397, 400, 665, 825, 1056LB, 373, 784, 826, 358, 395 Neurofilament light chain 340, 364, 389 Neurogranin 389 Neuroimaging 205, 352LB, 397, 400, 401 Neuroinflammation 70, 830 Neuronal injury 73, 383, 386, 387, 400 Neuropathogenesis 1056LB, 342, 373, 380, 387, 389, 398 Neuropenetration 400 Neuropsychiatric adverse events 372 Neuropsychologic performance 360, 394, 352LB, 381 Nevirapine 758, 759, 808 New antiretroviral 436 Next generation sequencing (NGS) 178, 192, 198, 218, 293, 71, 715LB NK cells 273, 274, 328, 579 Non-AIDS events 592, 591, 598, 600, 602, 647, 668 Non-birth cohort 517 Non-Hodgkin lymphoma 604 Noncommunicable diseases 639, 644 Nonhuman primates 1056LB, 1057LB, 123, 20, 332 Nonnucleoside reverse transcriptase inhibitor 316, 430, Neuropsychology 826 Neurosyphilis 749, 750 Neutralization 177 Neutralizing antibodies 1057LB, 190, 247, 798 Neutrophils 231

Keyword Index

452LB, 462, 484, 490, 501, 506 Nontargeted screening 956 Non–AIDS-defining cancers 474, 606 Normalized optical density 881

Mouse Model 328 Mozambique 581 MTCT 754 Mucosal 231, 379 · Barrier 210

Novel regimen 80LB NS5A 140, 562, 563

Phylogeography 195 Physical Function 667 PI-containing ARV regimens 756, 778 Pibrentasvir 413 PK and non-PK measures 976 Placenta 753 Plasma concentrations 426

· Inhibitor 565 · Mutation 561 Nuclear envelope 17, 18 Nuclear import 160LB, 17, 18 Nucleoside analog 405, 440, 579, 436, 440, 484

· Gene expression 241 · HIV-1 transmission 181LB · Immunity 216, 231, 276

CROI 2017 489